Anti-Cancer Chemotherapy for Colorectal Cancer - RETIRED | CMS Coverage Update

Summary: The Centers for Medicare & Medicaid Services modified its anti-cancer chemotherapy coverage policy for colorectal cancer, effective May 15, 2026, retiring the existing policy. Here's what billing teams need to know before that date.

This retirement affects how Medicare handles chemotherapy billing for colorectal cancer treatment. The Centers for Medicare & Medicaid Services issued this change without a replacement policy number listed, which creates real ambiguity for oncology billing teams who rely on this coverage policy as their claim documentation anchor. No specific CPT or HCPCS codes are listed in the policy data — we cover what that means for your charge capture below.

---

Quick-Reference Table

Field	Detail Copy
Payer	CMS (Centers for Medicare & Medicaid Services)
Policy	Anti-Cancer Chemotherapy for Colorectal Cancer — RETIRED
Policy Code	N/A
Change Type	Modified (Retirement)
Effective Date	May 15, 2026
Impact Level	High
Specialties Affected	Oncology, Hematology/Oncology, Infusion Therapy, Gastroenterology
Key Action	Confirm your MAC's local coverage determination before May 15, 2026, and update your claim documentation anchors accordingly

---

CMS Anti-Cancer Chemotherapy Coverage Policy for Colorectal Cancer: What the Retirement Means in 2026

When a CMS policy is retired, it doesn't automatically mean coverage stops. But it does mean the documentation framework your billing team has relied on — the specific criteria, indications, and medical necessity standards that gave your claims their backbone — is going away.

The CMS anti-cancer chemotherapy coverage policy for colorectal cancer has served as a national-level reference for Medicare billing on colorectal cancer treatment regimens. Its retirement on May 15, 2026, removes that reference point. What replaces it depends almost entirely on your Medicare Administrative Contractor.

This is the critical piece most billing teams will miss: CMS national policy retirements often shift authority down to the MAC level. That means coverage criteria, medical necessity documentation requirements, and prior authorization thresholds can now vary by region. If your practice spans multiple states or MACs, you may be dealing with different standards for the same chemotherapy claims.

The policy data provided does not list specific CPT or HCPCS codes. That's unusual for a chemotherapy policy, and it reinforces the MAC-level ambiguity. Your team should not assume any specific code set is safe from scrutiny after May 15, 2026.

---

CMS Colorectal Cancer Chemotherapy Coverage Criteria and Medical Necessity Requirements 2026

Before the retirement, this coverage policy established the national framework for what CMS considered medically necessary chemotherapy for colorectal cancer. That framework covered treatment regimens for Stage II, III, and IV colorectal cancer, including adjuvant and palliative chemotherapy.

With the retirement, medical necessity documentation becomes more — not less — important. Without a standing national coverage determination to cite, your claims need to carry stronger clinical documentation on their own. That means complete diagnosis coding, treating physician attestation of medical necessity, and clear alignment between the treatment regimen billed and the patient's documented stage and treatment plan.

Whether colorectal cancer chemotherapy is covered under Medicare after May 15, 2026, will depend on your MAC's local coverage determination. Some MACs have already published LCDs that address chemotherapy for colorectal cancer. Others have not. You need to know which situation applies to your region before the effective date.

Prior authorization requirements may also shift. If your MAC decides to introduce prior auth requirements for specific chemotherapy regimens in the absence of the national policy, your billing team needs to catch that change before claims go out. Check your MAC's website and sign up for their bulletin notifications now — not after the first denial hits.

CMS reimbursement rates for chemotherapy drugs administered in the outpatient setting run through the Medicare Part B drug fee schedule. That doesn't change with this retirement. What changes is the coverage policy scaffolding around those drugs. The reimbursement mechanism stays the same; the coverage justification pathway changes.

---

CMS Colorectal Cancer Chemotherapy Exclusions and Non-Covered Indications

The retired policy did not publish explicit exclusions in the data available here. But retirement of a coverage policy creates its own category of risk: claims that were previously supported by a national coverage determination now lose that explicit backing.

Chemotherapy regimens used off-label or for early-stage disease without strong clinical evidence are the most exposed. These claims were already scrutinized under the prior policy. Without a standing national framework, they face even higher claim denial risk post-retirement.

Investigational regimens — anything not yet established in NCCN guidelines or CMS's clinical trial coverage provisions — remain non-covered. The retirement of this policy doesn't open new doors for experimental treatment billing. If anything, it removes a layer of national coverage clarity that could be cited in support of some borderline indications.

---

Coverage Indications at a Glance

The policy data does not provide specific indication-level coverage criteria. The table below reflects what CMS has historically covered under this policy category, based on Medicare billing guidelines for anti-cancer chemotherapy. Confirm each indication with your MAC's current LCD before billing after May 15, 2026.

This table is based on historical CMS policy patterns, not codes or criteria listed in the policy data above. Verify all indications against your MAC's active LCD.

---

CMS Colorectal Cancer Chemotherapy Billing Guidelines and Action Items 2026

The retirement of this policy is a billing operations problem, not just a clinical one. Here's what your team needs to do before May 15, 2026.

Copy Action Items

---

CPT, HCPCS, and ICD-10 Codes for Anti-Cancer Chemotherapy Under CMS Colorectal Cancer Policy

The policy data provided does not list specific CPT, HCPCS, or ICD-10 codes. This is a significant gap for colorectal cancer chemotherapy billing, and your team should not treat it as meaning "all codes are unaffected."

Colorectal cancer chemotherapy billing typically involves drug administration codes, chemotherapy agent codes (HCPCS J-codes), and diagnosis codes for colorectal malignancies. The specific codes in your charge master that support colorectal cancer chemotherapy claims all carry exposure under this policy retirement.

What to do in the absence of listed codes: Pull your own internal utilization data. Look at every CPT administration code, every J-code for colorectal cancer chemotherapy drugs, and every colorectal malignancy ICD-10-CM diagnosis code you've billed against Medicare in the past 12 months. Those are your affected codes. Cross-reference each against your MAC's active LCD to confirm continued coverage after May 15, 2026.

Your MAC's LCD will list the covered diagnosis codes explicitly. That list becomes your new billing guideline. Any colorectal cancer diagnosis code not on your MAC's covered list is a denial risk — document it aggressively or flag it for clinical review before billing.

---